27 May 2026 : Clinical Research
Long-Term Durability and Dynamics of Anti-S-RBD IgG Response in Healthcare Workers: A Comparative Analysis of Homologous and Heterologous SARS-CoV-2 Vaccination Schedules in a 1-Year Serial Cross-Sectional Study
Çiğdem DemirelDOI: 10.12659/MSM.952930
Med Sci Monit 2026; 32:e952930
Table 5 Distribution of anti-S-RBD IgG according to time elapsed after vaccination in vaccine statuses.
| Group | Time (weeks) | n (%) | Median (AU/mL) | 95% CI | P value* | Effect size (ɛ2)** |
|---|---|---|---|---|---|---|
| SSSn=39 | ≤12 | 7 (17.9) | 78.2 | 71.4–85.1 | 0.987 | <0.01 |
| 13–24 | 8 (20.5) | 77.4 | 70.2–84.6 | |||
| 25–48 | 10 (25.6) | 77.1 | 69.8–84.3 | |||
| 49+ | 14 (35.9) | 77.0 | 69.5–84.2 | |||
| BBBn=67 | ≤12 | 7 (10.4) | 124.5 | 118.2–130.8 | 0.002 | 0.38 |
| 13–24 | 26 (38.8) | 115.3a | 109.1–121.5 | |||
| 25–48 | 20 (29.9) | 102.4a | 96.2–108.6 | |||
| 49+ | 14 (20.9) | 92.1,a | 85.8–98.4 | |||
| SSBn=60 | ≤12 | 3 (5.0) | 118.4 | 112.1–124.7 | 0.004 | 0.28 |
| 13–24 | 16 (26.7) | 110.2 | 104.0–116.4 | |||
| 25–48 | 12 (20.0) | 98.5,a | 92.3–104.7 | |||
| 49+ | 29 (48.3) | 89.4,a | 83.2–95.6 | |||
| SSBBn=90 | ≤12 | 13 (14.4) | 135.2 | 128.4–142.1 | 0.002 | 0.35 |
| 13–24 | 21 (23.3) | 122.1 | 115.3–128.9 | |||
| 25–48 | 37 (41.1) | 108.4,a | 101.6–115.2 | |||
| 49+ | 19 (21.1) | 98.4,a | 91.2–105.6 | |||
| SSBBBn=51 | ≤12 | 22 (43.1) | 129.4 | 122.6–136.2 | 0.013 | 0.22 |
| 13–24 | 10 (19.6) | 118.5 | 111.7–125.3 | |||
| 25–48 | 19 (37.3) | 104.2,a | 97.4–111.0 | |||
| 49+ | No data | No data | ||||
| * P value was calculated using the Kruskal-Wallis test. ** Epsilon-squared (ɛ) values of 0.01, 0.06, and 0.14 were interpreted as small, medium, and large effect sizes, respectively. a Statistically significant difference compared to the ≤12 weeks group (P b Statistically significant difference compared to the 13–24 weeks group (P | ||||||






